Transcription
A ComprehensiveBoard Review inHematology andMedical Oncology—A Virtual Live Streaming Course—September 27-October 2, 2021September 27-29, 2021:Benign and Malignant HematologySeptember 28-October 2, 2021:Malignant Hematology and Solid Tumor
A Comprehensive BoardReview in Hematologyand Medical Oncology— A Virtual Live Streaming Course —GOALThe course is a 6-day comprehensive review of current standards andpractices in the management of patients with blood disorders andmalignancy. The course is designed to enable the participant toeffectively prepare for the American Board of Internal Medicinecertification and recertification examinations in Hematology andMedical Oncology. Advances in clinical pharmacology, moleculargenetics and risk assessment, and radiation oncology will be included.EDUCATIONAL OBJECTIVESAt the conclusion of this educational activity, participants should beable to: Apply knowledge gained to prepare for the hematology and medicaloncology subspecialty and recertification examinations inhematology and medical oncology Utilize current standards of care for patients with cancer, blooddisorders and malignancies Demonstrate proficiency of knowledge in hematology and medicaloncology Incorporate recent advances in management of hematologic andoncologic patients; and Define molecular determinants of cancer risk and apply thisknowledge in practice.TARGET AUDIENCEThis program should be of interest to Physicians, Advanced PracticeProviders, APNs, and Nurses.EDUCATIONAL METHODS Lectures/Didactic Case-based Question-and-Answer Sessions (in board examinationformat) Virtual Live Streaming Course Canvas – an online course management systemEVALUATIONA course evaluation survey will provide participants with theopportunity to comment on the value of the program content to theirpractice decisions, performance improvement activities, or possibleimpact on patient health status. Participants will also have theopportunity to comment on any perceived commercial bias in thepresentations as well as to identify future educational topics.
ACCREDITATION/CREDIT DESIGNATIONThe University of Texas MD Anderson Cancer Center is accredited bythe Accreditation Council for Continuing Medical Education(ACCME) to provide continuing medical education for physicians.The University of Texas MD Anderson Cancer Center designates thislive activity for a maximum of 51.25 AMA PRA Category 1 Credits .Physicians should claim only the credit commensurate with the extentof their participation in the activity.MOC POINTSAmerican Board of Internal MedicineSuccessful completion of this CME activity, whichincludes participation in the evaluation component,enables the participant to earn up to 51.25 Medical Knowledge MOCpoints in the American Board of Internal Medicine’s (ABIM)Maintenance of Certification (MOC) program. Participants will earnMOC points equivalent to the amount of CME credits claimed for theactivity. It is the CME activity provider’s responsibility to submitparticipant completion information to ACCME for the purpose ofgranting ABIM MOC points. In order to receive MOC points, youmust pass the post-test with a score of 70% or higher.Participant completion data will be shared with and transmitted to theACCME on the participant’s behalf.Please Note: The deadline to claim MOC Points and CME Credits isNovember 2, 2021.CME CERTIFICATES AND ATTENDANCEVERIFICATION CERTIFICATESCertificates awarding AMA PRA Category 1 Credit or certificatesdocumenting attendance will be available to participants once theycomplete the on-line evaluation. To obtain a CME certificate,physicians must complete the on-line evaluation questionnaire.A record of attendance (certificate) will be available online to otherhealth care professionals for requesting credits in accordance withstate nursing boards, specialty societies, or other professionalassociations.PLANNING COMMITTEEMD Anderson Cancer CenterSharon Giordano, MD, MPH, Co-ChairTapan Kadia, MD, Co-ChairBonnie Glisson, MD, FACPBaylor College of MedicineMartha Mims, MD, PhD, Co-ChairShreyaskumar Patel, MDAlessandra Ferrajoli, MDNishin Bhadkamkar, MDFelisha Estelle
AGENDAMonday, September 27, 2021All time is Central Time (CT)6:45 am Virtual On-line Registration Check-in7:15Welcome and IntroductionSharon Giordano, MD, MPHChair, Department of Health ServicesMD Anderson Cancer CenterMartha Mims, MD, PhDSection Chief, Hematology/OncologyBaylor College of MedicineBENIGN HEMATOLOGY SESSIONGeneral Topics/Red Cell Disorders/Platelets7:30Iron Deficiency and Hemochromatosis8:15Hematopoietic Growth Factors9:00Bone Marrow Failure9:4510:00Leukopenia and LeukocytosisMatthew Heeney, MDMartha Mims, MD, PhDTimothy Olson, MD, PhDBreakNancy Berliner, MD10:45Issues in Transfusion Medicine11:45Q & A Panel DiscussionMatthew Heeney, MD; Martha Mims, MD, PhD;Timothy Olson, MD, PhD; and Nancy Berliner, MD12:00 pm Lunch BreakCoagulation/Platelets/Red Cell Disorders12:30Sickle Cell Anemias, Thalassemia, andHemoglobinopathiesAlice Ma, MD1:15Hemolytic Anemias2:00Approach to Anemia2:302:45Disorders of Platelet FunctionIberia Romina Sosa, MD, PhDAlice Ma, MDBreakA. Koneti Rao, MD, FACP3:30Thrombocytopenias4:15Q & A Panel Discussion4:30Alvin Schmaier, MDAlice Ma, MD; Iberia Romina Sosa, MD, PhD;A. Koneti Rao, MD, FACP; and Alvin Schmaier, MDAdjourn
Tuesday, September 28, 2021All time is Central Time (CT)Platelet/Red Cell Disorders/Transfusion Medicine7:30 amAntithrombotic & Antiplatelet Therapy8:15Normal Coagulation9:009:15Alvin Schmaier, MDKenneth Bauer, MDBreakCoagulation Factor Deficiencies, Includingvon Willebrand’s Disease and HemophiliasKenneth Bauer, MD10:00Hypercoagulable States11:00Q & A Panel Discussion11:15Benign Hematology Q & A Session11:55Stephan Moll, MDAlvin Schmaier, MD; Kenneth Bauer, MD; and StephanMoll, MDJahanavi Gollamudi, MDLunch BreakMALIGNANT HEMATOLOGY SESSIONLymphoma/Leukemia12:30 pm Classification of LymphomaLynne Abruzzo, MD, PhD1:15Aggressive Non‐Hodgkin LymphomaLoretta Nastoupil, MD2:00Break2:15Indolent Non‐Hodgkin LymphomaNathan Fowler, MD3:00Hodgkin LymphomaBarbara Pro, MD3:45Acute Lymphoblastic LeukemiaDaniel DeAngelo, MD, PhD4:30Q & A Panel DiscussionLynne Abruzzo, MD, PhD; Loretta Nastoupil, MD;Nathan Fowler, MD; Barbara Pro, MD; andDaniel DeAngelo, MD, PhD4:45Adjourn
Wednesday, September 29, 2021All time is Central Time (CT)Myeloma/Leukemia/MDS7:30 amMultiple Myeloma and Other Plasma CellDyscrasiasS. Vincent Rajkumar, MD8:30Chronic Lymphocytic Leukemia and HairyCell LeukemiaSusan O’Brien, MD9:15Chronic Myeloid Leukemia10:0010:15Myelodysplastic SyndromeJorge Cortes, MDBreakTapan Kadia, MD11:00Acute Myeloid Leukemia11:45Q & A Panel DiscussionCourtney DiNardo, MDS. Vincent Rajkumar, MD; Susan O’Brien, MD;Jorge Cortes, MD; Tapan Kadia, MD; andCourtney DiNardo, MD12:00 pm Malignant Hematology Q & A SessionKelly Chien, MD12:40Lunch BreakMPNs/Transplant/Infectious Disease1:15Myleoproliferative Neoplasms2:15Stem Cell Transplant Supportive Care3:153:30Infectious Complications in Cancer Patients4:154:30Srdan Verstovsek, MDBetty Hamilton, MDBreakSamuel Shelburne, MD, PhDQ & A Panel DiscussionSrdan Verstovsek, MD; TBA; andSamuel Shelburne, MD, PhDAdjourn
Thursday, September 30, 2021All time is Central Time (CT)SOLID TUMOR SESSIONPharmacology/Genetic Risk Factors/Neuro-Oncology7:30 amPharmacology I: Chemotherapy8:30Pharmacology II: Targeted Therapy (Alk,EGFR, VEGR, HER2, HH, mTOR, PARP)Chrystia Zobniw, PharmDWhitney Lewis, PharmD9:009:309:45Pharmacology III: Targeted Therapy (CD20,CD30, CD33, Proteasome, BCR-ABL/KIT,FLT3, IDH1/2, CDK4/6, PI3K)Brian Primeaux, PharmDBreakPharmacology IV: ImmunotherapyChrystia Zobniw, PharmD10:05Genetic Risk Factors10:50Neuro‐Oncology11:35Q & A Panel Discussion11:50Claudine Isaacs, MDAntonio Omuro, MDChrystia Zobniw, PharmD;Whitney Lewis, PharmD; Brian Primeaux, PharmD;Claudine Isaacs, MD; and Antonio Omuro, MDLunch BreakMelanoma/Sarcoma/Gynecologic Oncology12:15 pm MelanomaRodabe Amaria, MD1:00SarcomaShreyaskumar Patel, MD2:00Cervical CancerAlejandro Rauh Hain, MD2:45Break3:00Uterine CancerShannon Westin, MD3:30Ovarian Cancer and Unusual OvarianHistologiesShannon Westin, MD4:30Q & A Panel Discussion4:45Solid Tumor Q & A ‐ Session 1:Pharmacology/Genetic Risk Factors/NeuroOncology/ Melanoma/Sarcoma/GYN5:25Rodabe Amaria, MD; Shreyaskumar Patel, MD;Alejandro Rauh Hain, MD; and Shannon Westin, MDMark Lewis, MDAdjourn
Friday, October 1, 2021All time is Central Time (CT)Breast Cancer7:30 amScreening/Local Management of BreastCancerJennifer Litton, MD8:159:159:30Systemic Treatment of Primary Breast CancerIncluding HER2 Positive Breast DiseaseLisa Carey, MDBreakTreatment of Metastatic Breast CancerIncluding HER2 Positive Breast DiseaseMariana Chavez MacGregor, MD10:30Special Issues in Breast Cancer11:00Q & A Panel Discussion11:15ASH/ASCO Choosing WiselyRecommendations11:55Sharon Giordano, MDJennifer Litton, MD; Lisa Carey, MD;Mariana Chavez MacGregor, MD;and Sharon Giordano, MDRavin Garg, MDLunch BreakLung Cancer/Head and Neck Cancer/Thyroid Cancer12:30Early Stage and Locally Advanced Non‐SmallCell Lung CancerNasser Hanna, MD1:15Metastatic Non‐Small Cell Lung Cancer2:15Small Cell Lung Cancer2:453:00Head and Neck CancerNasser Hanna, MDLauren Byers, MDBreakWilliam N. William, Jr., MD3:45Thyroid Cancer4:15Q & A Panel Discussion4:30Solid Tumor Q & A ‐ Session 2: BreastCancer/Lung Cancer/Head and Neck Cancer/Thyroid Cancer5:10Naifa Busaidy, MDNasser Hanna, MD; Lauren Byers, MD;William N. William, Jr., MD; and Naifa Busaidy, MDRavin Garg, MDAdjourn
Saturday, October 2, 2021All time is Central Time (CT)Gastrointestinal Oncology7:30 amPancreaticobiliary Cancers/UnknownPrimaryRobert Wolff, MD8:309:309:45Gastroesophageal Cancers/ HepatocellularCarcinomaHarry Yoon, MDBreakColorectal Cancer: Biology and AdjuvantTherapyScott Kopetz, MD, PhD10:15Metastatic Colorectal Cancer and AnalCancerScott Kopetz, MD, PhD11:1511:30Q & A Panel DiscussionRobert Wolff, MD; Harry Yoon, MD;and Scott Kopetz, MD, PhDLunchGenitourinary Oncology12:00 pm Testicular CancerTimothy Gilligan, MD1:00Urothelial CancerArlene Siefker-Radtke, MD1:45Renal Cell CarcinomaEric Jonasch, MD2:30Break2:45Prostate CancerNicholas Mitsiades, MD, PhD4:00Q & A Panel DiscussionTimothy Gilligan, MD; Arlene Siefker-Radtke, MD;Eric Jonasch, MD; and Nicholas Mitsiades, MD, PhD4:15Solid Tumor Q & A ‐ Session 3:Gastrointestinal Oncology/GenitourinaryOncology4:55Tina Cascone, MD, PhDAdjourn
Guest FacultyLynne Abruzzo, MD, PhDThe Ohio State UniversityColumbus, OhioMark Lewis, MDIntermountain HealthcareMurray, UtahKenneth Bauer, MDBeth Israel Deaconess Medical CenterBoston, MassachusettsAlice Ma, MDUniversity of North Carolina –Chapel Hill School of MedicineChapel Hill, North CarolinaNancy Berliner, MDBrigham and Women’s HospitalBoston, MassachusettsLisa Carey, MDUNC Lineberger ComprehensiveCancer CenterChapel Hill, North CarolinaJorge Cortes, MDGerogia Cancer CenterAugusta, AtlantaDaniel DeAngelo, MDDana-Farber Cancer InstituteHarvard Medical SchoolBoston, MassachusettsStephan Moll, MDUniversity of North Carolina Schoolof MedicineChapel Hill, North CarolinaSusan O’Brien, MDUniversity of California, IrvineOrange, CaliforniaTimothy Olson, MD, PhDChildren’s Hospital of PhiladelphiaPhiladelphia, PennsylvaniaAntonio Omuro, MDYale Cancer CenterNew Haven, ConnecticutRavin Garg, MDMaryland Oncology Hematology Annapolis DivisionJohns Hopkins UniversityAnnapolis, MarylandBarbara Pro, MDRobert H. Lurie Cancer CenterNorthwestern University-FeinbergSchool of MedicineChicago, IllinoisTimothy Gilligan, MDCleveland ClinicCleveland, OhioS. Vincent Rajkumar, MDMayo Clinic – MinnesotaRochester, MinnesotaBetty Hamilton, MDCleveland ClinicCleaveland, OhioA. Koneti Rao, MD, FACPLewis Katz School of Medicine atTemple UniversityPhiladelphia, PennsylvaniaNasser Hanna, MDIndiana University Schoolof MedicineIndianapolis, IndianaMatthew Heeney, MDDana-Farber/Boston Children’sCancer and Blood Disorders CenterBoston, MassachusettsClaudine Isaacs, MDGeorgetown UniversityWashington, District of ColumbiaAlvin Schmaier, MDCase Western Reserve UniversityCleveland, OhioIberia Romina Sosa, MD, PhDFox Chase Cancer CenterPhiladelphia, PAWilliam William, Jr., MDBP HospitalSao Paulo, BrazilHarry Yoon, MDMayo Clinic – MinnesotaRochester, Minnesota
REGISTRATION INFORMATIONA Virtual Live Streaming Course.The Comprehensive Board Review in Hematology and MedicalOncology is going virtual. This program will be presented only as a livestreaming course. You will receive an email from the course platformto log in and access the live course online approximately a weekbefore the conference.PRESENTATIONS:Course syllabus will not be printed. Presentations (slides) will beavailable online via the course platform and Canvas. The PowerPointpresentations will be posted online as PDFs prior to the conference.You will receive an invitation email with directives to log in Canvas. T he Full Conference and Hematology Session will begin at 7:30 amon Monday, September 27. The Hematology Session will adjourn at4:30 pm on Wednesday, September 29, 2021. The full conference willadjourn at 4:55 pm on Saturday, October 2. The Oncology Session will begin at 7:30 am on Thursday, September30 and adjourn at 4:55 pm on Saturday, October 2.Advanced registration is encouraged. Please see the registration feespage.*NOTE: The conference registration fee includes the tuition, accessto course virtual platform with PDFs of the slides and Canvas - onlineweb-based system with recorded videos.The deadline for advanced registration is Friday, September 3, 2021. Register online at e registrations are not accepted.We accept the following forms of payment: Credit Cards (MasterCard, VISA, and American Express) Check (payable through U.S. banks only) Mail to: Continuing Professional Education – Unit 1781The University of Texas MD Anderson Cancer CenterP.O. Box 301407Houston, TX 77230-1407When registering online a receipt (confirmation letter) will beautomatically emailed to the e-mail address you list on the registrationform.REFUND/CANCELLATION POLICYThe registration fee, minus a 50 administrative handling fee, isrefundable if a written request is received on or before Friday,September 3, 2021. No refunds will be granted after that date. Therequest for a registration refund must include the tax identificationnumber of the company or institution if registration was paid by acompany or institution check. For additional information, contactContinuing Professional Education at 713-792-2223 or toll free at866-849-5866.
Continuing Professional Education reserves the right to cancelactivities prior to the scheduled date, if low enrollment or othercircumstances make it necessary. Each registrant will be notifiedby mail, e-mail, or at the phone or fax numbers given on theregistration form.In case of activity cancellation, the liability of Continuing ProfessionalEducation is limited to the registration fee. Continuing ProfessionalEducation will refund the full registration fee.Continuing Professional Education reserves the right to limit thenumber of participants in a program and is not responsible for anyexpenses incurred by an individual whose registration is notconfirmed and for whom space is not available. Please check thewebsite.PAST CONFERENCES REVIEWS AND TESTIMONIALS“The conference was well worth my time. It is nice to be ableto take in as much information as possible and havethe option of talking to the speakers afterwards. If this boardreview is still around in ten years (I hope it is), I will certainlyattend it again as I study for my recertification.”“Fantastic course! It helped pass my boards with flying colors!”“As a first time attendee and visitor to MD Anderson, the overallorganization and quality of activity was very impressive and met everyexpectation. Would recommend this activity to any colleague/associate.”“Excellent review course. The conference waswell organized and ran smoothly.”“Exceeded expectations; worth every penny.”“Superb conference. Exceptional, impressive”“Very well organized. Amazing how well support staff keptprogram on time, and fed everyone.”Please let us know what specific topics, issues, or questions you wishto see addressed or emphasized in this activity by emailing ContinuingProfessional Education at PEPinfo@mdanderson.org. All responseswill be forwarded to the Program Chairs for consideration.SPECIAL ASSISTANCEContact Felisha Estelle in Continuing Professional Education at713-745-0083 or 1-866-531-MOBR (6627) if you have any ADAaccommodation needs.
CONFERENCE REGISTRATION - D123392Comprehensive Board Review in Hematologyand Medical OncologySeptember 27-October 2, 2021CONFERENCE REGISTRATION FEESFull Conference - MDs, PhDs, DOs, PharmDs1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . 1,2001 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . 1,3001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,400Full Conference - Residents/Fellows/MD Anderson Alumni*1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . . 8001 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . 9001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,000Hematology Session - 3 days (Thursday - Saturday)MDs, PhDs, DOs, PharmDs1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . . 5501 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . 6001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650Hematology Session - 3 days (Monday - Wednesday)Residents/Fellows/MD Anderson Alumni*1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . . 3501 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . 4001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 450Oncology Session - 4 ½ days (Tuesday PM - Saturday)MDs, PhDs, DOs, PharmDs1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . . 5501 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . 6001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 650Oncology Session - 4 ½ days (Tuesday PM - Saturday)Residents/Fellows/MD Anderson Alumni*1 Postmarked on or before August 6, 2021. . . . . . . . . . . . . . . . . . . . . . . . . . . 3501 Postmarked on or before September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . 4001 Postmarked after September 3, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4501 Advanced Practice Providers/Nurses/Advanced Practice Nurses*. . . . . . . 4501 MD Anderson/Baylor Faculty/Staff. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5001 MD Anderson/Baylor Clinical Fellows*. . . . . . . . . . . . . . . . . . . . . . . . . . Exempt* A letter of introduction from the program director or chairpersonwith registration form is required to claim this reduced fee.Make check to:The University of Texas MD Anderson Cancer Center
2021 HEMATOLOGY AND MEDICALONCOLOGY BOARD REVIEW:COMPREHENSIVE PROGRAM MATERIALAVAILABLE FOR NON-ATTENDEESComprehensive source material can provide you with home-study.Designed for fellows-in-training, physicians planning to take theHematology or Medical Oncology certifying examination, orphysicians wishing to review the established standards of care inHematology or Medical Oncology.The conference registration fee includes the tuition,access to the course virtual platform with PDFs ofthe slides and Canvas (online web-based systemwith recorded videos).NOTE: The conference will be available through an onlinecourse management system (Canvas) where you will be able toview each recorded lecture. The full conference will be availableapproximately 10 days after the conference adjourns.Instructions for access to Canvas will be provided.CME Credits and MOC Points are awarded only byattending the virtual course.Available option to obtain course material:CANVAS - o nline web-based system with recorded videos(Log in instructions will be provided) Online site with downloadable audio & video for the entire2021 Course Each speaker’s complete PowerPoint slide presentation(Adobe Acrobat PDF file) Full color, just as presented Each speaker’s list of references Please allow 2-3 business days to process order before receivinglog in instructions DownloadableD123392/PS112004NON ATTENDEESCANVAS - online system with recorded videos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,000.00Please note: Flash drives are no longer available to purchase.Telephone orders are not accepted.Register online at https://mdanderson.cloud-cme.com/hmobr2021ALL SALES ARE FINAL.Make check or money order payable to: The University of Texas MD AndersonCancer Center. Please allow 2-3 business days to process order before receivinglog in instructions.
The University of Texas MD Anderson Cancer Center has implemented a processwhereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest thatcould potentially affect the information presented.MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical deviceproducts. Specific disclosure will be made to the participants prior to the educationalactivity.Agendas are subject to change because we are always striving to improve the qualityof your educational experience. MD Anderson may substitute faculty with comparableexpertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.Photographing, audio taping and videotaping are prohibited.
The University of Texas MD Anderson Cancer CenterContinuing Professional Education - Unit 1781176700/30/123392/41P.O. Box 301407Houston, Texas 77230-1407Non-Profit Org.U.S. PostagePAIDHouston, TXPermit No. 7052
The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy. The course is designed to enable the participant to effectively prepare for the American Board of Internal Medicine certification and recerti
